Ann: PromarkerD Intellectual Property portfolio expands, page-47

Its pleasing to see the SP holding up reasonably well on the back of ostensibly no news. I definitely agree with Bella 44 that PIQ should grab a very sizable and lucrative slice of the worlds pathology diagnostics for Diabetic Kidney disease. Whats problematic at the moment is they have not sold any tests, so we all wait for the various jurisdictions to start trialling what PIQ has revolutionised. Owl vs Fox makes the valid point that adopting new technologies takes time as people and institutions all balk at change. Lets hope management at PIQ have the temerity to employ the best marketing people so that the uptake of our new test brings benefits to stakeholders and patients alike reasonably quickly. Personally, this could easily be a ten bagger or better from the current SP. I am confident this investment will be very lucrative, so l hold firmly despite good paper profits because the true potential value of this company has not been realised by a long shot.